Pharmacokinetics and Pharmacodynamics of Vincristine Sulfate Liposome Injection (VSLI) in adults with acute lymphoblastic leukemia

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1139-1145

  Silverman, Jeffrey A ^a   Reynolds, Laurie ^b   Deitcher, Steven R ^a  

^a Talon Therapeutics Inc   (United States)

^b ICON Development Solutions   (United States)

Author keywords

Clinical pharmacology (CPH); Drug delivery (DEL); Oncology (ONC); Pharmacodynamics (PDY); Pharmacokinectics drug metabolism (PDM)

Indexed keywords

LIPOSOME; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; PERIPHERAL NEUROPATHY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

CLINICAL PHARMACOLOGY (CPH); DRUG DELIVERY (DEL); ONCOLOGY (ONC); PHARMACODYNAMICS (PDY); PHARMACOKINECTICS & DRUG METABOLISM (PDM);

ADMINISTRATION, INTRAVENOUS; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; INJECTIONS; LIPOSOMES; PERIPHERAL NERVOUS SYSTEM DISEASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE;

EID: 84892924472     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.155     Document Type: Article

References (38)

1. Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr. The vinca alkaloids: A new class of oncolytic agents. Cancer Res. 1963;23: 1390-1427.
2. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29(3):267-287.
3. van Tellingen O, Sips JH, Beijnen JH, Bult A, Nooijen WJ. Pharmacology, bioanalysis and pharmacokinetics of the vinca alkaloids and semisynthetic derivatives (review). Anticancer Res. 1992;12(5):1699-1715.
4. Degraeve N. Genetic and related effects of Vinca rosea alkaloids. Mutat Res. 1978;55(1):31-42.
5. Gidding CE, Meeuwsende Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol. 1999;44(3): 203-209.
6. Nelson RL, Dyke RW, Root MA. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev. 1980;7(suppl 1):17-24.
7. Owellen RJ, Root MA, Hains FO. Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 1977;37(8 Pt 1):2603-2607.
8. Sethi VS, Jackson DV, Jr., White DR, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res. 1981;41(9 Pt 1):3551-3555.
9. Allen TM. Liposomal drug formulations Rationale for development and what we can expect for the future. Drugs. 1998;56(5):747-756.
10. Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nanoparticles in cancer. Anticancer Agents Med Chem. 2006;6(6):513-523.
11. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 2008;97(11):4696-4740.
12. Burris HA, III, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colonyforming units in vitro. J Natl Cancer Inst. 1992;84(23): 1816-1820.
13. Georgiadis MS, Russell EK, Gazdar AF, Johnson BE. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res. 1997;3(3):449-454.
14. Jackson DV Jr, Bender RA. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res. 1979;39(11):4346-4349.
15. Krishna R, Webb MS, St Onge G, Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposomeencapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001;298(3): 1206-1212.
16. Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71(3):555-564.
17. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin- cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72(4):896-904.
18. Webb MS, Logan P, Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998;42(6):461-470.
19. O'Brien S, Schiller G, Lister J, et al. Highdose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosomenegative acute lymphoblastic leukemia. J Clin Oncol. 2013;31(6):676-683.
20. Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol. 2006;46(7):727-737.
21. Bedikian AY, Silverman JA, Papodopolous NE, et al. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol. 2010 1-8.
22. Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970;10(2):107-131.
23. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96(1):69-86.
24. Ratain MJ, Vogelzang NJ, Sinkule JA. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther. 1987;41(1):61-67.
25. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG. The pharmacokinetics of vincristine in man: Reduced drug clearance associated with raised serum alkaline phosphatase and doselimited elimination. Cancer Chemother Pharmacol. 1982;8(2):215-219.
26. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691-743.
27. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22(2):197-224.
28. Allen TM, Stuart DD. Liposome pharmacokinetics: Classical, sterically stabilized, cationic liposomes and immunoliposomes. InJanoff AS, ed. Liposomes Rational Design. New York: Marcel Dekker, Inc.; 1999. p 63-87.
29. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer. 1995;71(3):482-488.
30. Haim N, Epelbaum R, BenShahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2mg dose limit) in the treatment of lymphomas. Cancer. 1994;73(10):2515-2519.
31. Moore A, Pinkerton R. Vincristine: Can its therapeutic index be enhanced Pediatr Blood Cancer. 2009;53(7):1180-1187.
32. Verstappen CC, Koeppen S, Heimans JJ, et al. Doserelated vincristineinduced peripheral neuropathy with unexpected offtherapy worsening. Neurology. 2005;64(6):1076-1077.
33. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983;1(2):146-153.
34. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4(9):1295- 1306.
35. DeVita VT, Jr., Hubbard SM, Longo DL. The chemotherapy of lymphomas: Looking back, moving forward - the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987;47(22): 5810-5824.
36. Epelbaum R, Faraggi D, BenArie Y, et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer. 1990;66(6):1124-1129.
37. Boehlke L, Winter JN. Sphingomyelin/cholesterol liposomal vincristine: A new formulation for an old drug. Expert Opin Biol Ther. 2006;6(4):409-415.
38. Rodriguez MA, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive nonHodgkin lymphoma: Report of the pivotal phase 2 study. Cancer. 2009;115(15):3475-3482.